These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 28894550)
21. Screening for late-onset Pompe disease in Poland. Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121 [TBL] [Abstract][Full Text] [Related]
22. Prevalence of late-onset pompe disease in Portuguese patients with diaphragmatic paralysis - DIPPER study. Guimarães MJ; Winck JC; Conde B; Mineiro A; Raposo M; Moita J; Marinho A; Silva JM; Pires N; André S; Loureiro C Rev Port Pneumol (2006); 2017; 23(4):208-215. PubMed ID: 28499810 [TBL] [Abstract][Full Text] [Related]
23. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study. Wencel M; Shaibani A; Goyal NA; Dimachkie MM; Trivedi J; Johnson NE; Gutmann L; Wicklund MP; Bandyopadhay S; Genge AL; Freimer ML; Goyal N; Pestronk A; Florence J; Karam C; Ralph JW; Rasheed Z; Hays M; Hopkins S; Mozaffar T Neurol Genet; 2021 Dec; 7(6):e623. PubMed ID: 36299500 [TBL] [Abstract][Full Text] [Related]
24. Search for Pompe disease among patients with undetermined myopathies. Lindberg C; Anderson B; Engvall M; Hult M; Oldfors A Acta Neurol Scand; 2016 Feb; 133(2):131-135. PubMed ID: 26190396 [TBL] [Abstract][Full Text] [Related]
25. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618 [TBL] [Abstract][Full Text] [Related]
26. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398 [TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129 [TBL] [Abstract][Full Text] [Related]
28. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645 [TBL] [Abstract][Full Text] [Related]